AveXis, Inc. (NASDAQ:AVXS) VP Sukumar Nagendran sold 1,780 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $94.77, for a total transaction of $168,690.60. Following the completion of the transaction, the vice president now owns 1,780 shares of the company’s stock, valued at approximately $168,690.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Sukumar Nagendran also recently made the following trade(s):

  • On Wednesday, November 1st, Sukumar Nagendran sold 1,780 shares of AveXis stock. The shares were sold at an average price of $101.26, for a total transaction of $180,242.80.
  • On Monday, October 2nd, Sukumar Nagendran sold 1,780 shares of AveXis stock. The stock was sold at an average price of $97.25, for a total transaction of $173,105.00.

Shares of AveXis, Inc. (NASDAQ:AVXS) traded down $0.34 during mid-day trading on Tuesday, reaching $93.50. 350,535 shares of the company’s stock were exchanged, compared to its average volume of 426,264. AveXis, Inc. has a 12-month low of $44.68 and a 12-month high of $108.27.

AveXis (NASDAQ:AVXS) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.04). During the same quarter in the previous year, the business posted ($0.87) EPS. equities research analysts expect that AveXis, Inc. will post -6.23 EPS for the current year.

Several brokerages recently commented on AVXS. Evercore ISI began coverage on shares of AveXis in a report on Wednesday, August 16th. They set an “outperform” rating and a $120.00 target price for the company. Royal Bank Of Canada restated a “hold” rating and set a $92.00 target price on shares of AveXis in a report on Thursday, November 2nd. Chardan Capital restated a “buy” rating and set a $130.00 target price (up previously from $102.50) on shares of AveXis in a report on Friday, August 11th. BMO Capital Markets restated a “buy” rating and set a $123.00 target price on shares of AveXis in a report on Friday, August 11th. Finally, Wells Fargo & Company restated an “outperform” rating and set a $134.00 target price (up previously from $89.00) on shares of AveXis in a report on Tuesday, September 5th. Three investment analysts have rated the stock with a sell rating, three have assigned a hold rating and thirteen have given a buy rating to the stock. AveXis currently has a consensus rating of “Buy” and an average target price of $110.67.

A number of hedge funds have recently made changes to their positions in AVXS. Teachers Advisors LLC lifted its stake in AveXis by 2.6% in the first quarter. Teachers Advisors LLC now owns 54,217 shares of the company’s stock valued at $4,122,000 after acquiring an additional 1,387 shares during the last quarter. Morgan Stanley lifted its stake in AveXis by 8.4% in the first quarter. Morgan Stanley now owns 22,681 shares of the company’s stock valued at $1,724,000 after acquiring an additional 1,758 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its stake in AveXis by 7.0% in the first quarter. Schwab Charles Investment Management Inc. now owns 54,865 shares of the company’s stock valued at $4,172,000 after acquiring an additional 3,579 shares during the last quarter. Bank of Montreal Can lifted its stake in AveXis by 7,058.8% in the second quarter. Bank of Montreal Can now owns 30,425 shares of the company’s stock valued at $2,500,000 after acquiring an additional 30,000 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in AveXis by 41.7% in the second quarter. Russell Investments Group Ltd. now owns 24,871 shares of the company’s stock valued at $2,043,000 after acquiring an additional 7,321 shares during the last quarter. Hedge funds and other institutional investors own 92.88% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “AveXis, Inc. (AVXS) VP Sells $168,690.60 in Stock” was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/12/05/avexis-inc-avxs-vp-sells-168690-60-in-stock.html.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Insider Buying and Selling by Quarter for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.